{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '25', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Type of Control', 'Active Control with Placebo', 'NOTE: As of Amendment 007-06, the placebo treatment', 'is removed from the study.', 'Study Blinding', 'Double-blind', 'NOTE: As of Amendment 007-06, the study is', 'unblinded.', 'Masking', 'Participant or Subject', 'Investigator', 'Sponsor', 'Estimated Duration of Study', 'The Sponsor estimates that the study will require', 'approximately 5 years from the time the first participant (or', 'their legally acceptable representative) provides', \"documented informed consent until the last participant's\", 'last study-related contact.', 'Extension Study in China: The Sponsor estimates that the', 'study will require approximately an additional 1 year', \"(beyond the global study's last participant last study-related\", 'contact) from the time the first participant (or their legally', 'acceptable representative) provides documented informed', \"consent until the last participant's last study-related contact.\", 'NOTE: As of Amendment 007-06, enrollment in the', 'Extension Study in China has been stopped.', 'Number of Participants:', 'Global Study: Approximately 620 participants will be randomized.', 'Extension Study in China: Approximately 120 Chinese participants overall will be enrolled', 'in the global study and the extension study.', 'NOTE: As of Amendment 007-06, enrollment in the Extension Study in China has been', 'stopped.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '26', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'Intervention Groups and Duration:', 'Intervention', 'Groups', 'Regimen/', 'Intervention', 'Dose', 'Dose', 'Route of', 'Treatment', 'Group Name', 'Drug', 'Strength', 'Level', 'Admin.', 'Period', 'Use', 'IV', 'Standard of', 'Pembrolizumab', '100 mg/vial', '200 mg', 'Q3W', 'Infusion', 'Arm A', 'care/Experimental', 'Lenvatinib', '10 mg/4 mg', '20 mg', 'Oral', 'QD', 'Experimental', 'IV', 'Standard of', 'Pembrolizumab', '100 mg/vial', '200 mg', 'Q3W', 'Infusion', 'Arm B', 'care/Experimental', 'Placebo', 'NA', 'NA', 'Oral', 'QD', 'Placebo', 'Abbreviations: NA = not applicable; Q3W = every 3 weeks; QD = daily.', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the treatment groups. Participants remaining on treatment will receive open-label', 'pembrolizumab monotherapy as per protocol.', 'Total', '2 arms', 'Number of', 'Intervention', 'Groups/Arms', 'Duration of', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have', 'Participation', 'been removed from the study. This section has been updated', 'accordingly.', 'After a screening phase of up to 28 days, each participant received assigned', 'study intervention until one of the conditions for discontinuation of study', 'intervention was met (defined in Section 7.1).', 'Participants will be permitted to continue study intervention beyond RECIST', '1.1-defined PD as long as the treating investigator considers that the', 'participant may experience clinical benefit with continued treatment as per', 'iRECIST, and the participant is tolerating study intervention, until PD is', 'confirmed by iRECIST. All decisions to continue treatment beyond', 'confirmed PD by iRECIST must be approved by the Sponsor.', 'Participants who have been on pembrolizumab for at least 24 weeks and', 'attain a CR may consider stopping pembrolizumab treatment.', 'After the end of treatment, each participant will be followed for the', 'occurrence of AEs and spontaneously reported pregnancy, as described in', 'Section 8.4.5. Participants will not be required to continue with posttreatment', 'follow-up imaging for disease status.', 'All participants will be followed for OS until death, withdrawal of consent,', 'lost to follow-up, or the end of the study. The end of the study will be when', 'the last participant completes the last study-related telephone call or visit,', 'withdraws from the study, or is lost to follow-up (ie, the participant is unable', 'to be contacted by the investigator).', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'Confidential']\n\n###\n\n", "completion": "END"}